CAMBRIDGE, Mass., August 6, 2026
Amylyx Pharmaceuticals reported its second quarter 2026 financial results, highlighting significant progress across its clinical pipeline led by avexitide, an investigational GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH). The company confirmed that the last participant has completed the final study visit in the 16-week double-blind Phase 3 LUCIDITY trial, with topline data expected in late August or early September 2026. Amylyx is simultaneously advancing New Drug Application (NDA) readiness and commercial preparations for a potential 2027 launch, if approved. The company also reported a cash runway extending into 2028, providing financial support for its late-stage development programs and broader pipeline.
Phase 3 LUCIDITY Trial Approaches Key Data Readout
The Phase 3 LUCIDITY trial enrolled 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery in a randomized, double-blind, placebo-controlled study evaluating once-daily avexitide. The trial is assessing the FDA-agreed primary endpoint of reducing the composite of Level 2 and Level 3 hypoglycemic events over 16 weeks. Participants completing the blinded portion are eligible to enter a 32-week open-label extension. Avexitide has previously demonstrated statistically significant reductions in hypoglycemic events across multiple Phase 2 studies and has received FDA Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for relevant indications. Amylyx believes positive Phase 3 results could position avexitide as the first FDA-approved therapy specifically developed for PBH.
Pipeline Continues to Expand Beyond PBH
Beyond avexitide, Amylyx continued advancing multiple investigational programs during the quarter. The company presented Phase 1 data for AMX0114, an antisense oligonucleotide targeting calpain-2 for amyotrophic lateral sclerosis (ALS), demonstrating a favorable safety profile and supporting continued dose escalation. Cohorts 1 and 2 have completed enrollment, while Cohort 3 is currently recruiting participants. Amylyx also published and presented longer-term results from the Phase 2 HELIOS trial evaluating AMX0035 in Wolfram syndrome, showing sustained stabilization or improvement across pancreatic function, glycemic control, vision, and symptom measures over 96 weeks. Additionally, the company initiated a second research collaboration with Gubra A/S to identify new therapeutic candidates for rare endocrine diseases and continues IND-enabling studies for AMX0318, a long-acting GLP-1 receptor antagonist targeted for IND submission in 2027.
Advertisement
Financial Position Supports Late-Stage Development
Amylyx reported research and development expenses of $23.8 million for the second quarter of 2026, reflecting continued investment in avexitide while reducing spending on completed programs. Selling, general, and administrative expenses increased to $21.9 million, primarily driven by commercial launch preparations and legal costs. The company recorded a net loss of $43.4 million, while ending the quarter with $250.8 million in cash, cash equivalents, and short-term investments. Management stated that current resources are expected to fund operations into 2028, supporting planned regulatory submissions, commercialization activities, and continued advancement of its endocrine and neurodegenerative disease pipeline.
Source:Amylyx Pharmaceuticals release
